The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A first-in-human phase 1b study of a novel allosteric extracellular FGFR2 inhibitor alofanib in patients with refractory metastatic gastric cancer.
 
Sergei Tjulandin
Stock and Other Ownership Interests - RosPharmTech
Consulting or Advisory Role - AstraZeneca; Lilly; Merck; Roche
Speakers' Bureau - AstraZeneca; BioCad; Merck Sharp & Dohme; Novartis; Roche; SERVIER
Travel, Accommodations, Expenses - Merck Sharp & Dohme
 
Galina Statsenko
No Relationships to Disclose
 
Elena Artamonova
No Relationships to Disclose
 
Liubov Yu Vladimirova
No Relationships to Disclose
 
Natalia Besova
No Relationships to Disclose
 
Anastasia Mochalova
No Relationships to Disclose
 
Ivan Rykov
No Relationships to Disclose
 
Vladimir Moiseyenko
No Relationships to Disclose
 
Igor A. Utyashev
No Relationships to Disclose
 
Sergei Iugai
No Relationships to Disclose
 
Vasily Kazey
No Relationships to Disclose
 
Grigory Raskin
No Relationships to Disclose
 
Nadezhda Dragun
Employment - Ruspharmtech
 
Dmitry Reznikov
Employment - Ruspharmtech
 
Evgenia Gavrilova
Employment - Ruspharmtech
 
Ilya Tsimafeyeu
Leadership - Ruspharmtech
Stock and Other Ownership Interests - Merck; Ruspharmtech
Honoraria - Bristol-Myers Squibb/Celgene; Novartis; Pfizer
Consulting or Advisory Role - Novartis; Pfizer
Speakers' Bureau - AstraZeneca; Novartis; Pfizer; Ruspharmtech
Research Funding - Novartis (Inst); Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - Kidney Cancer Research Bureau; Oncomax LLC; Ruspharmtech